Page 78 - Tyrosine-Based Bioconjugations - Jorick Bruins
P. 78

Chapter 4
(32) van Geel, R., Wijdeven, M. A., Heesbeen, R., Verkade, J. M. M., Wasiel, A. A., van Berkel, S. S., and van Delft, F. L., Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates. Bioconjugate Chem. 2015, 26 (11), 2233-42.
(33) Blackman, M. L., Royzen, M., and Fox, J. M., Tetrazine ligation: Fast bioconjugation based on inverse-electron-demand Diels-Alder reactivity. J. Am. Chem. Soc. 2008, 130 (41), 13518-9.
(34) Wagner, K., Kwakkenbos, M. J., Claassen, Y. B., Maijoor, K., Bohne, M., van der Sluijs, K. F., Witte, M. D., van Zoelen, D. J., Cornelissen, L. A., Beaumont, T., et al., Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity. Proc. Natl. Acad. Sci. U. S. A. 2014, 111 (47), 16820-5.
(35) Rossin, R., van den Bosch, S. M., ten Hoeve, W., Carvelli, M., Versteegen, R. M., Lub, J., and Robillard, M. S., Highly Reactive trans-Cyclooctene Tags with Improved Stability for Diels- Alder Chemistry in Living Systems. Bioconjugate Chem. 2013, 24 (7), 1210-7.
(36) Castoldi, R., Schanzer, J., Panke, C., Jucknischke, U., Neubert, N. J., Croasdale, R., Scheuer, W., Auer, J., Klein, C., Niederfellner, G., et al., TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations. Protein Eng., Des. Sel. 2016, 29 (10), 467-75.
(37) Klein, C., Schaefer, W., and Regula, J. T., The use of CrossMAb technology for the generation of bi- and multispecific antibodies. mAbs 2016, 8 (6), 1010-20.
(38) Bhutani, D., and Lum, L. G., Activated T cells armed with bispecific antibodies kill tumor targets. Current Opinion in Hematology 2015, 22 (6), 476-83.
(39) Bruins, J. J., Albada, B., and van Delft, F., ortho-Quinones and Analogues Thereof: Highly Reactive Intermediates for Fast and Selective Biofunctionalization. Chem. - Eur. J. 2018, 24 (19), 4749-56.
(40) Thakur, A., Huang, M., and Lum, L. G., Bispecific antibody based therapeutics: Strengths and challenges. Blood Rev. 2018, 32 (4), 339-47.
(41) Dahlén, E., Veitonmäki, N., and Norlén, P., Bispecific antibodies in cancer immunotherapy. Ther. Adv. Vaccines Immunother. 2018, 6 (1), 3-17.
76























































































   76   77   78   79   80